Table 8 Summary of the outcome assessment schedule
Session | Summary of content |
|---|---|
Visit 0 | • Patient information (T/E) • Study consent (T/E) • Pre-assessment (T/E) • Background information (T/E) • Q-PLP (T/E) • PDI (T/E) • EQ-5D-5L (T/E) • PSEQ-2 (T/E) • PCS-SF (T/E) • PHQ-2 (T/E) • EXPECT-SF (T/E) |
Randomization | |
Visit 1 | • Treatment session (T) • Q-PLP (E) • OAT (E) • EXPECT-SF (E) • HCCQ-SF (E) |
Visit 2–14 | • Treatment session (T) • Q-PLP (E) |
Visit 15 | • Treatment session (T) • Q-PLP (E) • PDI (E) • EQ-5D-5L (E) • PSEQ-2 (E) • PCS-SF (E) • PHQ-2 (E) • PGIC (E) • HCCQ-SF (E) |
1-month follow-up | • Q-PLP (E) • PDI (E) • EQ-5D-5L (E) • PSEQ-2 (E) • PCS-SF (E) • PHQ-2 (E) |
3-month follow-up | |
6-month follow-up | |